1235 related items for PubMed ID: 18405796
21. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.
Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, Knobil K.
J Allergy Clin Immunol; 2000 Dec; 106(6):1088-95. PubMed ID: 11112891
[Abstract] [Full Text] [Related]
22. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, Mechali D, Chan R, Pedersen S.
Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
[Abstract] [Full Text] [Related]
23. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
Koenig SM, Murray JJ, Wolfe J, Andersen L, Yancey S, Prillaman B, Stauffer J, Dorinsky P.
Respir Med; 2008 May; 102(5):665-73. PubMed ID: 18328683
[Abstract] [Full Text] [Related]
24. Adding salmeterol to fluticasone propionate or increasing the dose of fluticasone propionate in patients with asthma.
Delea TE, Hagiwara M, Stempel DA, Stanford RH.
Allergy Asthma Proc; 2010 May; 31(3):211-8. PubMed ID: 20615321
[Abstract] [Full Text] [Related]
25. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
O'Connor RD, Stanford R, Crim C, Yancey SW, Edwards L, Rickard KA, Dorinsky P.
Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
[Abstract] [Full Text] [Related]
26. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S.
J Med Econ; 2011 Dec; 14(6):769-76. PubMed ID: 21942463
[Abstract] [Full Text] [Related]
27. Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.
Nelson HS.
J Allergy Clin Immunol; 2001 Feb; 107(2):398-416. PubMed ID: 11174215
[Abstract] [Full Text] [Related]
28. Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation.
Hagiwara M, Delea TE, Stanford RH.
J Asthma; 2011 Sep; 48(7):721-8. PubMed ID: 21793768
[Abstract] [Full Text] [Related]
29. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast.
Orsini L, Limpa-Amara S, Crown WH, Stanford RH, Kamal K.
Ann Allergy Asthma Immunol; 2004 May; 92(5):523-9. PubMed ID: 15191020
[Abstract] [Full Text] [Related]
30. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM.
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[Abstract] [Full Text] [Related]
31. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L, Forget A, Ramachandran S.
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[Abstract] [Full Text] [Related]
32. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies.
Delea TE, Hagiwara M, Dalal AA, Stanford RH, Blanchette CM.
Curr Med Res Opin; 2009 Jan; 25(1):1-13. PubMed ID: 19210134
[Abstract] [Full Text] [Related]
33. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids.
Chan J, Hui RL, Spence MM.
J Manag Care Pharm; 2007 Jan; 13(1):21-7. PubMed ID: 17269833
[Abstract] [Full Text] [Related]
34. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily.
Kerwin EM, Nathan RA, Meltzer EO, Ortega HG, Yancey SW, Schoaf L, Dorinsky PM.
Respir Med; 2008 Apr; 102(4):495-504. PubMed ID: 18206361
[Abstract] [Full Text] [Related]
35. Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis.
Tunceli O, Williams SA, Kern DM, Elhefni H, Pethick N, Wessman C, Zhou S, Trudo F.
J Allergy Clin Immunol Pract; 2014 Apr; 2(6):719-26. PubMed ID: 25439363
[Abstract] [Full Text] [Related]
36. Adherence and persistence with fluticasone propionate/salmeterol combination therapy.
Bender BG, Pedan A, Varasteh LT.
J Allergy Clin Immunol; 2006 Oct; 118(4):899-904. PubMed ID: 17030244
[Abstract] [Full Text] [Related]
37. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma.
Masoli M, Weatherall M, Holt S, Beasley R.
Thorax; 2005 Sep; 60(9):730-4. PubMed ID: 16135679
[Abstract] [Full Text] [Related]
38. Inhaled corticosteroid use and outcomes in pregnancy.
Schatz M, Leibman C.
Ann Allergy Asthma Immunol; 2005 Sep; 95(3):234-8. PubMed ID: 16200813
[Abstract] [Full Text] [Related]
39. Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol.
Blais L, Beauchesne MF, Forget A.
Respir Med; 2009 Feb; 103(2):237-43. PubMed ID: 18930647
[Abstract] [Full Text] [Related]
40. Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs*.
Delea TE, Stanford RH, Hagiwara M, Stempel DA.
Curr Med Res Opin; 2008 Dec; 24(12):3435-42. PubMed ID: 19032125
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
